These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 34185336)

  • 61. COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
    Del Poeta G; Bomben R; Polesel J; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Postorino M; Laureana R; Pasqualone G; Steffan A; Gentile M; Zucchetto A; Gattei V
    Hematol Oncol; 2021 Dec; 39(5):712-714. PubMed ID: 34462939
    [No Abstract]   [Full Text] [Related]  

  • 62. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
    Tadmor T; Benjamini O; Braester A; Rahav G; Rokach L
    Leukemia; 2021 Sep; 35(9):2727-2730. PubMed ID: 34376803
    [No Abstract]   [Full Text] [Related]  

  • 63. Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis.
    Sakuraba A; Luna A; Micic D
    J Hematol Oncol; 2022 Feb; 15(1):15. PubMed ID: 35123511
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study).
    Royo-Cebrecos C; Robert-Montaner Ï; Vilanova D; Bailles E; Serrano-Pons J; Valero O; Buldon JM; Bermudez-de-Castro L; Mahia E; Pujadas J; Cobo F; Piqué JM; Albiol S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2883-2892. PubMed ID: 35809113
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
    Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
    Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Warm autoimmune hemolytic anemia and IgM-monoclonal gammopathy following BNT162b2 COVID-19 vaccine in a patient with splenic marginal zone lymphoma].
    Sogabe N; Kuno M; Nakagama Y; Makuuchi Y; Harada N; Takakuwa T; Okamura H; Hirose A; Nishimoto M; Nakashima Y; Koh H; Nakamae M; Kido Y; Nakamae H; Hino M
    Rinsho Ketsueki; 2022; 63(10):1379-1385. PubMed ID: 36351643
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Assessment of salivary antibody response to BNT162b2 mRNA COVID-19 vaccination.
    Lapić I; Šegulja D; Rogić D
    J Med Virol; 2021 Sep; 93(9):5257-5259. PubMed ID: 34009653
    [No Abstract]   [Full Text] [Related]  

  • 68. Anti-spike antibody response to the COVID vaccine in lymphoma patients.
    Della Pia A; Kim GYG; Ip A; Ahn J; Liu Y; Kats S; Koropsak M; Lukasik B; Contractor A; Amin K; Ayyagari L; Zhao C; Gupta A; Batistick M; Leslie LA; Goy AH; Feldman TA
    PLoS One; 2022; 17(12):e0266584. PubMed ID: 36454941
    [TBL] [Abstract][Full Text] [Related]  

  • 69. COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.
    Ito Y; Honda A; Kurokawa M
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e691-e707. PubMed ID: 35459624
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The antibody response of haematological malignancies to COVID-19 infection and vaccination.
    Seebacher NA
    Br J Cancer; 2022 Mar; 126(5):691-692. PubMed ID: 35017657
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Time to optimize vaccination strategies in blood cancer patients.
    Muhsen IN; Heslop HE
    Br J Haematol; 2024 Aug; 205(2):406-408. PubMed ID: 38895787
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
    Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
    Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
    [TBL] [Abstract][Full Text] [Related]  

  • 73. COVID-19 in patients with hematologic malignancy.
    Langerbeins P; Hallek M
    Blood; 2022 Jul; 140(3):236-252. PubMed ID: 35544585
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem.
    Sertić Z; Lucijanić M; Bašić-Kinda S; Serventi Seiwerth R; Periša V; Sertić D; Coha B; Pulanić D; Perić Z; Desnica L; Mikulić M; Vodanović M; Radman-Livaja I; Šegulja D; Rogić D; Valković T; Aurer I; Duraković N
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428459
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.
    Piechotta V; Mellinghoff SC; Hirsch C; Brinkmann A; Iannizzi C; Kreuzberger N; Adams A; Monsef I; Stemler J; Cornely OA; Bröckelmann PJ; Skoetz N
    Blood Cancer J; 2022 May; 12(5):86. PubMed ID: 35641489
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Mellinghoff SC; Mayer L; Robrecht S; Weskamm LM; Dahlke C; Gruell H; Schlotz M; Vanshylla K; Schloser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
    Haematologica; 2022 Oct; 107(10):2480-2484. PubMed ID: 35734927
    [No Abstract]   [Full Text] [Related]  

  • 77. Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
    Kontandreopoulou CN; Solomou EE; Kolorizos E; Diamantopoulos PT
    Ann Hematol; 2024 Jul; ():. PubMed ID: 39008060
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era.
    Zerbit J; Detroit M; Meyer A; Decroocq J; Deau-Fischer B; Deschamps P; Birsen R; Mondesir J; Franchi P; Miekoutima E; Guerin C; Batista R; Bouscary D; Willems L; Vignon M
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366475
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review.
    Keshavarz S; Keshavarz S; Ziamajidi N; Daei S
    Chonnam Med J; 2023 Jan; 59(1):24-30. PubMed ID: 36794237
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside.
    Laracy JC; Kamboj M; Vardhana SA
    Curr Opin Infect Dis; 2022 Aug; 35(4):271-279. PubMed ID: 35849516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.